{"id":"NCT02454933","sponsor":"AstraZeneca","briefTitle":"Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours","officialTitle":"A Phase III, Multi-Centre, Open Label, Randomized Study to Assess the Efficacy and Safety of AZD9291 in Combination With MEDI4736 Versus AZD9291 Monotherapy in Patients With Locally Advanced or Metastatic Epidermal Growth Factor Receptor T790M Mutation-positive Non-Small Cell Lung Cancer Who Have Received Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy (CAURAL)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-07-15","primaryCompletion":"2017-08-21","completion":"2023-06-21","firstPosted":"2015-05-27","resultsPosted":"2018-08-10","lastUpdate":"2024-09-19"},"enrollment":29,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Locally Advanced or Metastatic EGFR T790M+ NSCLC"],"interventions":[{"type":"DRUG","name":"AZD9291","otherNames":[]},{"type":"DRUG","name":"MEDI4736","otherNames":[]}],"arms":[{"label":"MEDI4736 & AZD9291 Combination","type":"EXPERIMENTAL"},{"label":"AZD9291 Monotherapy","type":"EXPERIMENTAL"}],"summary":"A Phase III, Multi-Centre, Open Label, Randomized Study to Assess the Efficacy and Safety of AZD9291 in Combination with MEDI4736 versus AZD9291 Monotherapy in patients with Locally Advanced or Metastatic Epidermal Growth Factor Receptor T790M mutation-positive Non-Small Cell Lung Cancer who have received Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy","primaryOutcome":{"measure":"Number of Subjects With Adverse Events (AEs) as a Measure of the Safety and Tolerability of Osimertinib in Combination With Durvalumab","timeFrame":"From Baseline up to primary analysis data cut-off (up to 24 months).","effectByArm":[{"arm":"Osimertinib 80 mg + Durvalumab 10mg/kg","deltaMin":12,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":16},"locations":{"siteCount":13,"countries":["Canada","South Korea","Taiwan"]},"refs":{"pmids":[],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=3824&filename=d5165c00001_CSP.pdf","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=3824&filename=d5165c00001_SAP.pdf","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5165C00001&amp;attachmentIdentifier=6ca2ff84-5370-43f5-947d-78cc8acda613&amp;fileName=d5165c00001-study-synopsis_CAURAL_CSR_synopsis_Redacted_with_correction.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5165C00001&amp;attachmentIdentifier=6e0ef65b-c5cd-4551-a00b-f41d0e1a0f73&amp;fileName=d5165c00001-Study_Report-Addendum_Synopsis_Jul2018_Redacted.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":17},"commonTop":["Diarrhoea","Paronychia","Dermatitis acneiform","Pruritus","Decreased appetite"]}}